QR код

Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study

Objectives: Subcutaneous administration of pertuzumab and trastuzumab offers a faster alternative to intravenous infusion for patients with HER2-positive breast cancer. However, real-world data on its impact on costs and capacity remain limited. Therefore, this study aimed to compare healthcare reso...

Повний опис

Збережено в:
Автори: Michiel Zietse, Jacky Hu, Esther R. van Staveren, Leontine E.A.M.M. Spierings, Agnes Jager, Birgit C.P. Koch, Ron H.J. Mathijssen, Roelof W.F. van Leeuwen, Frederick W. Thielen
Формат: Artigo
Мова:Inglês
Опубліковано: Elsevier 2025-12-01
Серія:Breast
Предмети:
HER2-Positive breast cancer
Pertuzumab and trastuzumab
Subcutaneous administration
Intravenous administration
Healthcare resource utilization
Cost analysis
Онлайн доступ:http://www.sciencedirect.com/science/article/pii/S0960977625005909
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси